1 May 2018 - BioCryst Pharmaceuticals today announced that the EMA has approved peramivir with the brand name of Alpivab, a single intravenous infusion for the treatment of uncomplicated influenza in adults and children from the age of 2 years.

The EMA’s approval of Alpivab under the centralised licensing procedure provides marketing authorisation for all 28-member states of the European Union, Norway and Iceland. Previously, peramivir injection (Rapivab, Rapiacta, Peramiflu) has received approval for commercialisation in the United States, Canada, Australia, Japan, Taiwan and Korea.

BioCryst has a license agreement with Seqirus regarding peramivir. As we have previously disclosed, BioCryst and Seqirus are engaged in a formal dispute resolution process. The dispute involves many items under the contract including, but not limited to, the EMA approval milestone of $5 million dollars, which BioCryst maintains is now due under the parties’ agreement.

Rea BioCryst Pharmaceuticals press release